|
1
|
Brundage MD, Davies D and Mackillop WJ:
Prognostic factors in non-small cell lung cancer: a decade of
progress. Chest. 122:1037–1057. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Danenberg PV: Thymidylate synthase - a
target enzyme in cancer chemotherapy. Biochim Biophys Acta.
473:73–92. 1977.
|
|
3
|
Wada H, Hitomi S and Teramatsu T: Adjuvant
chemotherapy after complete resection in non-small cell lung
cancer. West Japan Study Group for Lung Cancer Surgery. J Clin
Oncol. 14:1048–1054. 1996.
|
|
4
|
Nakano J, Huang C, Liu D, et al:
Evaluation of biomarkers associated with 5-FU sensitivity for
non-small-cell lung cancer patients postoperatively treated with
UFT. Br J Cancer. 95:607–615. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nakagawa T, Otake Y, Yanagihara K, et al:
Expression of thymidylate synthase is correlated with proliferative
activity in non-small cell lung cancer (NSCLC). Lung Cancer.
43:145–149. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kaira K, Ohde Y, Nakagawa K, et al:
Thymidylate synthase expression is closely associated with outcome
in patients with pulmonary adenocarcinoma. Med Oncol. 29:1663–1672.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kaira K, Serizawa M, Koh Y, et al:
Expression of thymidylate synthase, orotate
phosphoribosyltransferase and dihydropyrimidine dehydrogenase in
thymic epithelial tumors. Lung Cancer. 74:419–425. 2011. View Article : Google Scholar
|
|
8
|
Takeda M, Okamoto I, Hirabayashi N, et al:
Thymidylate synthase and dihydropyrimidine dehydrogenase expression
levels are associated with response to S-1 plus carboplatin in
advanced non-small cell lung cancer. Lung Cancer. 73:103–109. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sun JM, Han J, Ahn JS, et al: Significance
of thymidylate synthase and thyroid transcription factor 1
expression in patients with nonsquamous non-small cell lung cancer
treated with pemetrexed-based chemotherapy. J Thorac Oncol.
6:1392–1399. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Righi L, Papotti MG, Ceppi P, et al:
Thymidylate synthase but not excision repair cross-complementation
group 1 tumor expression predicts outcome in patients with
malignant pleural mesothelioma treated with pemetrexed-based
chemotherapy. J Clin Oncol. 28:1534–1539. 2010. View Article : Google Scholar
|
|
11
|
Zucali PA, Giovannetti E, Destro A, et al:
Thymidylate synthase and excision repair cross-complementing
group-1 as predictors of responsiveness in mesothelioma patients
treated with pemetrexed/carboplatin. Clin Cancer Res. 17:2581–2590.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kaira K, Okumura T, Ohde Y, et al:
Prognostic significance of thymidylate synthase expression in the
adjuvant chemotherapy after resection for pulmonary metastases from
colorectal cancer. Anticancer Res. 31:2763–2771. 2011.
|
|
13
|
Shirasaka T, Shimamato Y, Ohshimo H, et
al: Development of a novel form of an oral 5-fluorouracil
derivative (S-1) directed to the potentiation of the tumor
selective cytotoxicity of 5-fluorouracil by two biochemical
modulators. Anticancer Drugs. 7:548–557. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kawahara M, Furuse K, Segawa Y, et al:
Phase II study of S-1, a novel oral fluorouracil, in advanced
non-small-cell lung cancer. Br J Cancer. 85:939–943. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shih C, Chen VJ, Gossett LS, et al:
LY231514, a pyrrolo[2,3-d] pyrimidine-based antifolate that
inhibits multiple folate-requiring enzymes. Cancer Res.
57:1116–1123. 1997.
|
|
16
|
Giovannetti E, Backus HH, Wouters D, et
al: Changes in the status of p53 affect drug sensitivity to
thymidylate synthase (TS) inhibitors by altering TS levels. Br J
Cancer. 96:769–775. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gomez HL, Santillana SL, Vallejos CS, et
al: A phase II trial of pemetrexed in advanced breast cancer:
clinical response and association with molecular target expression.
Clin Cancer Res. 12:832–838. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rose MG, Frarrell MP and Schmitz JC:
Thymidylate synthase: a critical target for cancer chemotherapy.
Clin Colorectal Cancer. 1:220–229. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sasaki R, Komaki R, Macapinlac H, et al:
[18F]fluorodexyglucose uptake by positron emission
tomography predicts outcome of non-small-cell lung cancer. J Clin
Oncol. 23:1136–1143. 2005.
|
|
20
|
Higashi K, Ueda Y, Arisaka Y, et al:
18F-FDG uptake as a biologic prognostic factor for
recurrence in patients with surgically resected non-small cell lung
cancer. J Nucl Med. 43:39–45. 2002.
|
|
21
|
Bernard F, Sterman D, Smith RJ, et al:
Prognostic value of FDG PET imaging in malignant pleural
mesothelioma. J Nucl Med. 40:1241–1245. 1999.PubMed/NCBI
|
|
22
|
Song YS, Lee WW, Chung JH, et al:
Correlation between FDG uptake and glucose transporter type 1
expression in neuroendocrine tumors of the lung. Lung Cancer.
61:54–60. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kaira K, Okumura T, Ohde Y, et al:
Correlation between 18F-FDG uptake on PET and molecular
biology in metastatic pulmonary tumors. J Nucl Med. 52:705–711.
2011.PubMed/NCBI
|
|
24
|
Kaira K, Endo M, Abe M, et al: Biologic
correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake
on positron emission tomography in thymic epithelial tumors. J Clin
Oncol. 28:3746–3753. 2010.
|
|
25
|
Atkin GK, Daley FM, Bourne S, et al: The
impact of surgically induced ichaemia on protein levels in patients
undergoing rectal cancer surgery. Br J Cancer. 95:928–933. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kaira K, Endo M, Shukuya T, et al:
18F-FDG uptake on PET could be a predictive marker of
excision repair cross-complementation group 1 (ERCC1) expression in
patients with thoracic neoplasms? Neoplasma. 59:257–263. 2012.
View Article : Google Scholar
|
|
27
|
Kaira K, Ohde Y, Endo M, et al: Expression
of 4F2hc (CD98) in pulmonary neuroendocrine tumors. Oncol Rep.
26:931–937. 2011.PubMed/NCBI
|
|
28
|
Kaira K, Oriuchi N, Takahashi T, et al:
L-type amino acid transporter 1 (LAT1) expression in malignant
pleural mesothelioma. Anticancer Res. 31:4075–4082. 2011.PubMed/NCBI
|
|
29
|
Ceppi P, Volante M, Saviozzi S, et al:
Squamous cell carcinoma of the lung compared with other histotypes
shows higher messenger RNA and protein levels for thymidylate
synthase. Cancer. 107:1589–1596. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hashimoto H, Ozeki Y, Sato M, et al:
Significance of thymidylate synthase gene expression level in
patients with adenocarcinoma of the lung. Cancer. 106:1595–1601.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ibe T, Shimizu K, Nakano T, et al:
High-grade neuroendocrine carcinoma of the lung shows increased
thymidylate synthase expression compared to other histotypes. J
Surg Oncol. 102:11–17. 2010. View Article : Google Scholar
|
